Clinical trial
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)
NCT07400107 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- May 20, 2026
- Completion date
- January 26, 2029
- Enrollment
- 1,000 (estimated)
- Sites
- 120
Conditions
As the registry lists them; a condition with its own page is linked.